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Abstract 
Increased  risk  of  osteoporosis,  fractures,
and avascular necrosis (AVN) has been sug-
gested  in  multiple  sclerosis  (MS).  Patients
with  MS  are  often  exposed  to  corticosteroid
treatment  (CST)  during  the  disease  course
and conflicting reports exist regarding compli-
cations of CST. Our study aims to investigate
the association between cumulative doses of
CST and radiographic evaluation of AVN of the
femoral head in MS. Twenty-six MS patients
(mean  age,  38.4±10  yr)  were  enrolled  and
prospectively evaluated for AVN by magnetic
resonance imaging (MRI). The mean disease
duration  was  11.5±8.5  years  and  mean
expanded disability status scale (EDSS) score
was 3±2. The cumulative dosage of CST varied
between 20 g and 60 g; patients were grouped
into two categories: 1) CST between 20-40 g,
17  (65%)  patients;  2)  CST  ≥40  g;  9  (35%)
patients. The relationship between cumulative
CST  dosage  and  MRI  diagnosis  of  AVN  was
stat  istically  insignificant  (P>0.9).  Clarifi  -
cation of the cumulative effect of CST in the
development of AVN is of great importance for
future long-term steroid treatment strategies.
Introduction 
An increased risk of osteoporosis, fractures,
and avascular necrosis (AVN) has been sug-
gested in cases of multiple sclerosis (MS).
1-3
Although the exact mechanism of AVN is poor-
ly  understood,  the  most  common  etiological
event is reported as trauma and most of the
non-traumatic AVN cases are related to long-
term corticosteroid treatment (CST). However,
the impact of dosage and duration of CST is
not  apparent.  Patients  with  MS  are  often
exposed to pulse methylprednisolone applica-
tions during the disease course and conflicting
reports exist regarding complications of CST.
4
Our study aims to investigate the association
between  the  cumulative  dosage  of  CST  and
AVN of the femoral head in MS.
Materials and Methods 
This study was carried out in the setting of
a MS center at the Okmeydani Training and
Research Hospital, Istanbul. After approval was
obtained  from  the  Okmeydani  Training  and
Research Hospital ethical committee, 26 clin  -
ically  definite  MS  patients
5 were  identified
  retrospectively from a larger cohort of patients
who were followed in the MS outpatient clinic.
Identified patients were evaluated prospective-
ly  for  AVN.  Asymptomatic  patients  who
received at least 20 g methylprednisolone dur-
ing the whole course of the disease and with
no known AVN were enrolled into the study.
The inclusion criteria included patients who
did not have an acute attack during the past
four  weeks  or  any  steroid  pulse  treatment
three months prior to the study. Patients were
excluded if comorbidities including thyroid or
parathyroid  abnormalities,  diabetes  mellitus,
renal failure, hypertension, and autoimmune
rheumatic diseases were present. The purpose
of the test was explained fully to the patients
and informed consent was obtained. Patients
were evaluated by an experienced neurologist
by routine neurological examination including
assessment using the expanded disability sta-
tus  scale  (EDSS).
6 AVN  of  the  femur  was
assessed  bilaterally  by  magnetic  resonance
imaging (MRI) by a radiologist blinded to the
clinical characteristics. A 1.5-TGE Signo Excite
MRI device with 0.4 mm sections in coronal,
transverse,  and  sagittal  planes  was  utilized.
The  Ficat  Arlet  classification  was  used  for
radio  logical evaluation and all the signs of the
particular grading system were required to be
present for grading.
7-9 Patients with grades 3
and  4  were  accepted  as  presenting  with  a
radio  graphic  diagnosis  of  AVN  (RAVN)  (see
Appendix). Biochemical bone markers includ-
ing  serum  calcium,  magnesium,  and  phos  -
phorus,  alkaline  phosphates  (ALP),  serum
parathyroid  hormone  (PTH)  level,  and  25-
hydroxyvitamin  D  (25(OH)D)  were  also
assessed.
Statistical Analysis 
Descriptive  statistics  were  applied  to  the
demographic  features  of  the  cohort.  The
Wilcoxon rank test was applied for continuous
variables and the Kruskal-Wallis rank test was
used for ordinal and continuous variables. The
Chi-square test (normally distributed param  -
eters) and Mann-Whitney U test (not normally
distributed parameters) were used to compare
the groups. A P<0.05 was considered statis  -
tically significant. 
Results 
We  identified  26  clinically  definite  MS
patients (15 females, 58%), with a mean age of
38.4±10 years.
5 The mean disease duration was
11.5±8.5 years and the mean EDSS score for the
patient group was 3±2 (Table 1). Biochemical
determinants were found to be within the nor-
mal range (Table 2). There was no relationship
between bone biochemical markers and RAVN.
10
The cumulative dosage of CST varied between
20 g and 60 g, and the patients were grouped
into two categories as follows: 1) CST of 20-40 g,
17  (65%)  patients;  2)  CST  ≥40  g,  9  (35%)
patients.  The  total  number  of  patients  with
RAVN  was  6  (23%).  The  distribution  of  the
patients with RAVN according to CST dosage
was as follows: 1) CST of 20-40 g, 4 patients
(15%) had RAVN; 2) CST ≥40 g, 2 patients (8%)
presented with RAVN. The relationship between
cumulative CST dosage and RAVN was statisti-
cally insignificant (P>0.9). However, a statisti-
cally  significant  association  was  observed
between  cumulative  CST  dosage,  age,  EDSS,
and disease duration (P<0.0001) (Table 3).
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We aimed to raise the question of the effects
of the cumulative CST on the development of
RAVN.  Recent  studies  implicated  high-dose
CST for immunosuppression after organ trans-
plantation, as well as for rheumatological and
autoimmune  diseases,  as  a  risk  factor  for
development of atraumatic AVN.
11-13 The most
common reason for steroid application is gen-
erally rheumatic diseases like systemic lupus
erythematosus  or  rheumatoid  arthritis.  The
discussion  over  the  exact  nature  of  AVN  in
these diseases, a vasculitic process or CST, is
still an unresolved issue.
4,14 In one study, the
frequency of AVN between the treatment group
and the controls was investigated and found to
be  statistically  significant,  which  supported
the claim that high doses of steroids given in a
short time course would constitute an inde-
pendent risk for AVN.
4 Another study evaluated
the frequency of AVN among kidney transplant
recipients  and  showed  that  the  cumulative
steroid  dosage  was  higher  among  the  AVN
group than the control group. The study sug-
gested that reduction or early withdrawal of
steroids was the only efficient preventive treat-
ment  for  AVN.
13 In  our  study,  we  failed  to
demonstrate  a  significant  relationship
between RAVN and cumulative steroid dosage.
However, our diagnosis was based on radio  -
graphic findings and clinical presentation was
not evaluated. In addition, it would be useful to
investigate a correlation between the dosage
of CST used and the grade of AVN. For our
study  purposes,  only  the  presence  of  RAVN
(patients with AVN grades 3 and 4) was docu-
mented and a correlation between grading of
RAVN and CST dosage was not assessed fur-
ther in the study group. Small sample size and
lack of a control group are also limitations of
our report and studies with a longer term fol-
low-up  in  a  large  cohort  are  warranted.
However, our study aimed to investigate a very
important  question  about  the  dose-related
effects of CST and, to date, this issue has not
been clarified. Clarification of the cumulative
effect of CST in the development of AVN is of
great importance for future long-term steroid
treatments in MS as well as for routine clinical
practice where repeated CST is administered.
Appendix
• Grade  0:  no  clinical  and  X-ray  findings,
double-line sign on MRI. 
• Grade 1: joint is normal. The femoral head
is spherical with slight osteoporosis on X-
ray and a single line on T1 and double line
on T2, which demarcates necrotic bone. 
• Grade  2:  double-line  sign,  reactive  bone
demarcates the area of infarct. The joint is
normal and the femoral head is still spher-
ical. 
• Grade 3: loss of the spherical shape of the
femoral  head,  fracture  of  subchondral
bone, and crescent sign on X-ray. 
• Grade  4:  further  collapse  of  the  femoral
head, articular cartilage destruction, and
joint space narrowing. 
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Table 1. Demographic and clinical characteristics.
Gender (F:M) 2:1
Age (yr) 38.4±10
DD (yr) 11.5±8.5
Dx (%)
RRMS 17 (63)
SPMS 9 (27)
EDSS 3±2
# Patients according to cumulative CST (%)
20-40 g 17 (65%)
>40 g 9 (35%)
Distribution of AVN (%)
20-40 g 4 (15%)
>40 g 2 (8%)
DD, disease duration; RRMS, relapsing, remitting MS; SPMS, secondary progressive MS; EDSS, expanded disability status scale; CST, cortico -
steroid; AVN, avascular bone necrosis.
Table 2. Biochemical bone markers in the patient group.
Normal range Results Significance
Calcium (mg/dL) 9-10.6 9.7±0.5 P>0.25
Phosphorus (mg/dL)  2.5-45 4.6±2.2 P>0.5
Magnesium (mg/dL)  1.2-2.5 1.6±0.7 P>0.6
PTH (ng/mL)  0.15-0.6 0.4±0.1 P>0.95
25(OH) D (ng/mL)  11-45 37.4±4.3 P>0.3
ALP (U/L) 43-122 65.7±14.4 P>0.5
Values are expressed as the mean with standard deviation and P-values. PTH, parathyroid hormone; 25(OH) D, 25-hydroxyvitamin D; ALP, alka-
line phosphates.
Table 3. Distribution of demographics and clinical data according to cumulative cortico  -
steroid treatment dosage.
Cumulative CST dose 20-40 g Cumulative CST dose ≥40 g
Age 32.3±5.5 50.0±4.4
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Values are expressed as the mean with standard deviation. CST, corticosteroid treatment; EDSS, expanded disability status scale; 
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